News

In this video, the first in a 6-part series, panelists discuss recent advancements in PsO management.

Discover cutting-edge insights on schizophrenia, mood disorders, and digital therapeutics at the 2025 Southern California Psychiatry Conference.

Majcher discusses innovations in ocular imaging and the importance of educating patients on early warning signs of myopia to halt disease progression.

Thomas discusses emerging therapies, new technologies, and the reform needed to help these new developments reach the patients in need of them.

Study findings highlight the cost-effectiveness of more frequent HCV testing among people who inject drugs compared with no testing and less frequent testing.

Discover how recent advancements in biologic therapies transform severe asthma treatment, emphasizing personalized care and the importance of biomarker-driven decisions.

The FDA also announced an updated PDUFA date of December 13, 2025 for the self-administered nasal spray.

Capricor Therapeutics intends to resubmit a BLA for the potential first-in-class treatment with topline data from the ongoing HOPE-3 trial in Q3 2025.

Sandforth discussed his research that found that early prediabetes remission conferred greater protective effects against T2D than later remission.

Shaker shares how allergist-immunologists can use brief CBT, motivational interviewing, and risk reframing to shift patients’ fear of their food allergies into confidence.

Nontargeted screening identified more HCV infections than targeted screening, but both approaches led to minimal linkage to care and SVR12.

New research highlights significant declines in cardiovascular screenings for U.S. adults with disabilities during the COVID-19 pandemic, revealing ongoing healthcare disparities.

Landela’s research on an impoverished community in South Africa encourages clinicians to help similar populations get the care they need.

Explore the transformative potential of MDMA-assisted therapy and psychedelics in treating PTSD and addiction, offering hope where traditional methods fail.

Contrary to earlier research, a Framingham Heart Study analysis found no significant dementia risk tied to transient ischemic attack over 2 decades.

Nguyen spoke to the importance of being aware of heightened stress, anxiety, and depression due to myopia’s long-term treatment requirements.

Overexposure to mobile phones and similar devices can impact ocular and mental health; Roe suggests methods of managing screen time.

Transcend Therapeutics' TSND-201 gains FDA Breakthrough Therapy designation, offering new hope for rapid PTSD treatment with promising clinical trial results.

Actual LLT use was significantly lower than the proportion of guideline-eligible patients for statins, ezetimibe, and PCSK9i.

This announcement highlights Pelthos Therapeutics’ launch of berdazimer (ZELSUVMI) topical gel 10.3% for molluscum contagiosum.

Lonsberry recommends alternative approaches to manage postoperative pain, balancing the need for relief against the risk of addiction and death.

New data from a UMichigan survey found that 8% of preventative aspirin users had not even discussed their use with any health care provider.

The initial batch of published CRLs are associated with since-approved applications in an effort to increase transparency and provide insight into the decision-making process.

This study highlights the rate of sodium-glucose cotransporter 2 inhibitor (SGLT2i) use for heart failure within US ambulatory cardiovascular care settings.

Discover how structured routines and exercise enhance mental health for those with bipolar disorder, fostering stability, and community support.

The prespecified analysis of FINEARTS-HF found finerenone’s impact on HF events, cardiovascular death, and symptoms was not impacted by frailty.

Johnson & Johnson seeks FDA approval for lumateperone (CAPLYTA) to significantly reduce schizophrenia relapse risk. Company submits an sNDA.

Whitley speaks to the plethora of available biologics, the choice paralysis that can accompany the wide range of options, and the future of the industry.